Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen

Executive Summary

Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.
Advertisement

Related Content

Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says
Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says
Abbott/Millennium Metabolic Disease Deal Aims For 4-5 Drugs In 10 Years
Abbott/Millennium Metabolic Disease Deal Aims For 4-5 Drugs In 10 Years
Aventis/Introgen Adenoviral Gene Therapy In Phase III For Head/Neck Cancer
Advertisement
UsernamePublicRestriction

Register

PS037611

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel